Relevant publications on prospective randomized studies concerning residual tumor rate and recurrence-free survival rate for photodynamic diagnosis for urothelial bladder carcinoma. All study ...

Researchers at Winship Cancer Institute of Emory University have identified a novel type of immune cell, called the stem-like CD4 T cell, that plays a pivotal role in anti-tumor immunity.

Patients with advanced bladder cancer that had spread to other parts of the body (metastasized) have responded well in a phase I clinical trial of an investigational drug, TYRA-300. The drug ...

1INSERM U1015, Gustave Roussy Cancer Campus, Bâtiment de Médecine Moléculaire, Villejuif, France. 10Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université ...

Three months after our third child was born, he was diagnosed with stage IV squamous cell carcinoma. He thought he had a hemorrhoid, doctors said it was a tumor. They also said the cancer had ...

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...

(Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a confirmatory trial.

The rest of the cancer earnings came from Gilead’s cell therapy portfolio. More recently, Gilead CEO Daniel O’Day reported that Trodelvy clocked a 23% increase year-over-year for the second quarter to ...

In May, Gilead Sciences announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC). The TROPiCS-04 study evaluated Trodelvy ...

This dataset includes 33 different cancers, such as adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast cancer (BRCA), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), ...